Submissions from 2024
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies, Mansoor Saleh; Minal Barve; Vivek Subbiah; Kyriakos Papadopoulos; Daniel Morgensztern; Niharika Mettu; Sameek Roychowdhury,; Iben Spanggaard; Incyte International Biosciences Sàrl, Switzerland; and Chenwei Tian
Regulatory approval of clinical trials: is it time to reinvent the wheel?, Mansoor Saleh, Karishma Sharma, Aisleen Shamshudin, Innocent Abayo, Stacey Gondi, and Noureen Karimi
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya, Tom White, Viknesh Selvarajah, Fredrik Wolfhagen, Nils Svangård, Gayathri Mohankumar, Peter Fenici, Kathryn Rough, Nelson Onyango, Mansoor Saleh, and Innocent Abayo
Submissions from 2023
Breast cancer clinical trials in East Africa, Karishma Sharma, Joseph Abuodha, Manel Haj Mansour, Noureen Karimi, Diana Omare, Yuashita Hussein, and Mansoor Saleh
Submissions from 2022
Promoting Best Practice in Cancer Care in Sub Saharan Africa, Karishma Sharma, Shahin Sayed, and Mansoor Saleh
Submissions from 2020
Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians., Mansoor Saleh, Gurudatta Naik, Penelope Jester, Cynthia Joiner, Elizabeth Westfall, David W. Kimberlin, James Willig, David Redden, Juliette Southworth, and Mark T. Dransfield
Submissions from 2017
Abstract A12: Ethnic differences in the clinical and pathological characteristics of breast cancer among Kenyan women, Shahin Sayed, Zahir Moloo, Ronald Wasike, Asim Jamal, Peter Bird, Maya Palakal, Gretchen Gierach, and Mansoor Saleh
Submissions from 2016
Breast camps for awareness and early diagnosis of breast cancer in countries with limited resources: A multidisciplinary model from Kenya, Shahin Sayed, Zahir Moloo, Anthony Ngugi, Rose Ndumia, Ronald Wasike, Mansoor Saleh, Anderson Mutuiri, Abdul Aziz, Kibet Kibor, and Jonathan Wawire
Submissions from 2011
Pathologic characteristics of breast cancer with special emphasis on prevalence of triple-negative breast cancer from Kenya: A 4-year experience., Shahin Sayed, Zahir Moloo, Ronald Wasike, RR Chauhan, A Ndonga, ME Trinkaus, Y Rahim, H Wedad, and Mansoor Saleh
Submissions from 2008
A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients, C. Falkson, J. F. Rossman, L. Nabell, J. Carpenter, Mansoor Saleh, J. O'Malley, and A. Forero
A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer, A. Forero-Torres, J. Galleshaw, C. Jones, I. Percent, L. Nabell, J. Carpenter, C. Falkson, H. Krontiras, K. Bland, and Mansoor Saleh
A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas, Mansoor Saleh, I. Percent, T. E. Wood, J. Posey III, J. Shah, R. Carlisle, S. Wojtowicz-Praga, and A. Forero-Torres
Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC), A. D. Seidman, A. K. Conlin, A. Bach, A. M. Brufsky, Mansoor Saleh, D. Lake, M. N. Dickler, G. D'Andrea, T. A. Traina, and C. A. Hudis
Submissions from 2007
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel, Tomasz Beer, Celestia Higano, Mansoor Saleh, Robert Dreicer, Gary Hudes, Joel Picus, Mark Rarick, Louis Fehrenbacher, and Alison Hannah
Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with Idiopathic Thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study., James Bussel, Gregory Cheng, Lidia Kovaleva, Mansoor Saleh, Balkis Meddeb, Bhabita Mayer, J. Lee Fraser, and Manuel Aivado
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura, James Bussel, Bhabita Mayer, Nicole Stone, Michael Arning, Drew Provan, and Mansoor Saleh
Changing treatment paradigms for myelodysplastic syndromes in a community oncology practice: Georgia cancer specialists' experience, Bruce Feinberg, James Gilmore, Wendy Hawke Lenz, Carlos Franco, Tom Gondesen, and Mansoor Saleh
Bendamustine in non-hodgkin lymphoma: The double-agent that came from the cold war, Andres Forero-Torres and Mansoor Saleh
A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report, A. Forero-Torres, I. Percent, J. Galleshaw, L. Nabell, J. Carpenter, C. Falkson, C. Jones, H. Krontriras, J. De Los Santos, and Mansoor Saleh
A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report, A. Forero-Torres, I. Percent Percent, J. Galleshaw, L. Nabell, C. Falkson, C. Jones, H. Krontriras, J. De Los Santos, and Mansoor Saleh
Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer, L. Garrison, J. Cassidy, Mansoor Saleh, F. Lee, R. Mena, J. Fuloria, V. Chang, T. Ervin, P. Stella, and L. Saltz
B1-06: Multicenter, randomized study of docetaxel versus docetaxel plus oblimersen in patients previously treated for non-small cell lung cancer (NSCLC), Roy S. Herbst, Rafat Ansari, V Gorbunova, G Manikhas, Mansoor Saleh, Thomas Boyd, Christopher Azzoli, Francisco Robert, Loretta Itri, and Robert Chapman
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators, Tomasz M. Beer, Christopher W. Ryan, Peter M. Venner, Daniel P. Petrylak, Gurkamal S. Chatta, J. Dean Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor Saleh, and David Waterhouse
Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers, H. C. Pitot, Mansoor Saleh, J. Holmlund, J. Maleski, and A. Forero
Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC), Mansoor Saleh, M. A. Socinski, D. Trent, T. Dobbs, L. M. Zehngebot, M. A. Levine, and P. J. Stella
3003 ORAL cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial, Werner Scheithauer, A. Sobrero, H.J. Lenz, J. Maurel, M. Lutz, G. Middleton, Mansoor Saleh, A. Zubel, K. Williams, and H.A. Burris III
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T), L. Sylvester, L. Laufman, K. Jabboury, Mansoor Saleh, K. Tkaczuk, F. Volterra, J. Arnott, A. Hannah, C. Sidor, and A. Hannah
Submissions from 2006
Bexarotene improves median survival (MS) in untreated, advanced NSCLC, when given in combination with carboplatin/paclitaxel, R. Bordoni, Mansoor Saleh, S. Khanwani, T. Page, M. Auerbach, F. Steinbaum, and R. Ghalie
Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor., James B. Bussel, Gregory Cheng, Mansoor Saleh, Lidia Kovaleva, Nicole Stone, Bhabita Mayer, Julian Jenkins, and Andrew Provan
Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects, J. Bussel, Mansoor Saleh, D. Provan, N. Stone, J. M. Hamilton, H. Hassani, B. Mayer, J. Uhl, J. Jenkins, and J. Glaspy
Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results., Sven De Vos, Shaker R. Dakhil, Peter McLaughlin McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Charles Holladay, Mark Knapp, Anthony Boral, and Tracy Zhang
The safety profile of eltrombopag, a novel oral platelet growth factor, in thrombocytopenic patients and healthy subjects, D. Provan, Mansoor Saleh, S. Goodison, R. Rafi, N. Stone, J. M. Hamilton, H. Hassani, B. Mayer, J. Uhl, and J. Jenkins
Burden of illness of chronic, adult idiopathic thrombocytopenic purpura (ITP): A retrospective, longitudinal, cohort study, Mansoor Saleh and Kelly Grotzinger
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes, James Slack, John D. Hainsworth, James Mason, Mansoor Saleh, David Rizzieri, Dan Douer, and Alan F. List
Submissions from 2005
Bexarotene improves TTP in untreated, advanced NSCLC, when given in combination with carboplatin/paclitaxel, R. Bordoni, Mansoor Saleh, M. Auerbach, F Steinbaum, J. D. Cuevas, S. Harris, and B. Howell
Bortezomib plus rituximab in patients with indolent non-hodgkin's lymphoma (NHL): A phase 2 study., Sven de Vos, Shaker Dakhil, Peter McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, and Martha Glenn
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non–small-cell lung cancer, Francisco Robert, George Blumenschein, Roy S. Herbst, Frank Fossella, Jennifer Tseng, Mansoor Saleh, and Michael Needle
Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer, Pierre L. Triozzi, Graeme B. Bolger, Jeffrey Neidhart Neidhart, John J. Rinehart, Mansoor Saleh, Karen O. Allen, Sandra Sellers, and Mary Waddell
Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: Interim analysis, D. K. Washington, A. M. V. Storniolo, Mansoor Saleh, E. Tan-Chiu, A. Hagey, D. M. Medina, K. A. Meek, P. Cernohous, and G. B. Gordon Gordon
Submissions from 2004
Weekly oxaliplatin (OXA), 5-fluorouracil (FU) and leucovorin (LV) as first line treatment for advanced colorectal cancer (CRC) –A phase II study, A. Athanasiadis, N. Pissanidis, Mansoor Saleh, A. Moshidis, A. Chatzichristou, N. Makrantonakis, P. Kamentsidis, I. Natsiopoulos, and C. Christakis
cMulticenter, prospective, randomized, phase-II trial of sequential and concurrent oral bexarotene in combination with chemotherapy, in previously untreated patients with advanced NSCLC, R. Bordoni, L. Zemsky, Mansoor Saleh, C. Powell, and S. Harris
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma, Mohamad Hussein, Mansoor Saleh, Farhad Ravandi, James Mason, Robert Rifkin, and Ralph Ellison
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with Non-Hodgkin’s Lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy., Mark Kaminski, Andrew Zelenetz, Oliver Press, Mansoor Saleh, John Leonard, Louis Fehrenbacher, Andrew Lister, Stewart Kroll, Richard Wahl, and Susan Knox